Therefore, in the present study we analyzed whether a long-term pretreatment of ovarian cancer cells with anti-EGFR TKIs for several days and weeks (“sensitization”) could enable or enhance susceptibility to the EGFR antibody cetuximab in terms of cell viability. Here, EGFR is linked to ovarian carcinoma.